MX392972B - Metodo para utilizar ciclodextrina. - Google Patents

Metodo para utilizar ciclodextrina.

Info

Publication number
MX392972B
MX392972B MX2020000205A MX2020000205A MX392972B MX 392972 B MX392972 B MX 392972B MX 2020000205 A MX2020000205 A MX 2020000205A MX 2020000205 A MX2020000205 A MX 2020000205A MX 392972 B MX392972 B MX 392972B
Authority
MX
Mexico
Prior art keywords
cellular
cyclodextrin
diabetes
cholesterol
relating
Prior art date
Application number
MX2020000205A
Other languages
English (en)
Spanish (es)
Other versions
MX2020000205A (es
Inventor
Alessia Fornoni
Gomez Sandra Merscher
Original Assignee
L&F Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L&F Res Llc filed Critical L&F Res Llc
Publication of MX2020000205A publication Critical patent/MX2020000205A/es
Publication of MX392972B publication Critical patent/MX392972B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020000205A 2012-04-13 2013-04-12 Metodo para utilizar ciclodextrina. MX392972B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624087P 2012-04-13 2012-04-13
PCT/US2013/036484 WO2013155485A2 (en) 2012-04-13 2013-04-12 Method of using cyclodextrin

Publications (2)

Publication Number Publication Date
MX2020000205A MX2020000205A (es) 2022-06-06
MX392972B true MX392972B (es) 2025-03-21

Family

ID=49328287

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020000205A MX392972B (es) 2012-04-13 2013-04-12 Metodo para utilizar ciclodextrina.
MX2014012200A MX371073B (es) 2012-04-13 2013-04-12 Método para utilizar ciclodextrina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014012200A MX371073B (es) 2012-04-13 2013-04-12 Método para utilizar ciclodextrina.

Country Status (8)

Country Link
US (4) US10195227B2 (enExample)
EP (2) EP4299121A3 (enExample)
JP (4) JP6491089B2 (enExample)
CN (2) CN111419870A (enExample)
CA (1) CA2870316C (enExample)
ES (1) ES2959119T3 (enExample)
MX (2) MX392972B (enExample)
WO (1) WO2013155485A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392972B (es) * 2012-04-13 2025-03-21 L&F Res Llc Metodo para utilizar ciclodextrina.
EP2968083B1 (en) 2013-03-12 2021-09-22 Primal Therapies, Inc. Dental composition comprising chelator and base
JP6418911B2 (ja) * 2014-11-18 2018-11-07 学校法人中部大学 Ｇｌｐ−１分泌促進剤
CA2988529A1 (en) 2015-06-10 2016-12-15 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN105395549A (zh) * 2015-11-03 2016-03-16 天津医科大学总医院 烟酸的新用途
EP3515501A1 (en) * 2016-09-19 2019-07-31 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
WO2018075622A1 (en) * 2016-10-19 2018-04-26 University Of Miami Materials and methods for modulating insulin signaling and preserving podocyte function
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
US11925659B2 (en) 2018-10-29 2024-03-12 Cyclo Therapeutics, Inc. Methods for treating Alzheimer's disease
AU2020204925B2 (en) 2019-01-03 2025-11-20 Cyclarity Therapeutics, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
PH12021552553A1 (en) * 2019-04-16 2022-06-20 Celagenex Res India Pvt Ltd Synergistic lipid controlling compositions
KR20220098009A (ko) * 2019-11-11 2022-07-08 아츠오 오치 체세포를 재프로그래밍하기 위한 방법 및 키트
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
PE20231169A1 (es) * 2020-08-27 2023-07-26 Beren Therapeutics P B C Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas
WO2022047241A1 (en) * 2020-08-27 2022-03-03 Beren Therapeutics P.B.C. Methods for the treatment of cholesterol crystal embolization with cyclodextrins
EP4203973A4 (en) * 2020-08-27 2024-08-21 Beren Therapeutics P.B.C. METHOD FOR PREVENTING CHOLESTEROL CRYSTAL EMBOLISATION WITH CYCLODEXTRINS
CN112089843B (zh) * 2020-10-13 2022-11-04 合肥工业大学 一种抗心力衰竭的联用组合药物及其在制备抗心力衰竭药物中的应用
WO2022178318A1 (en) * 2021-02-18 2022-08-25 Beren Therapeutics P.B.C. Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
CN113295793B (zh) * 2021-05-20 2022-11-04 复旦大学附属中山医院 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用
EP4198061A4 (en) * 2021-09-01 2024-10-23 Renatus Inc. PHARMACEUTICAL COMPOSITION COMPRISING A GAMMA-CYCLODEXTRIN POLYMER AND ITS USE
KR20240160120A (ko) 2022-02-18 2024-11-08 베렌 테라퓨틱스 피.비.씨. 하이드록시프로필-베타-사이클로덱스트린의 조성물 및 이의 정제 방법

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672100B2 (ja) * 1989-11-15 1994-09-14 株式会社上野製薬応用研究所 利尿剤
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
EP1125584A4 (en) 1998-10-30 2005-01-12 Takeda Chemical Industries Ltd PREPARATIONS CONTAINING BETACELLULIN PROTEIN
US6756504B2 (en) * 2000-04-19 2004-06-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
JP4418751B2 (ja) 2002-08-19 2010-02-24 アート・ジェン・コンプレクサス・インコーポレイテッド 食物脂肪複合化剤を含む組成物およびそれらの利用法
JP2004323443A (ja) * 2003-04-25 2004-11-18 Tokai Univ 抗血栓薬
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US7276351B2 (en) 2003-09-10 2007-10-02 Seahorse Bioscience Method and device for measuring multiple physiological properties of cells
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
CN1282425C (zh) * 2004-06-22 2006-11-01 王美岭 苹果醋营养品及其生产方法
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
AU2006208109A1 (en) 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Formulations for injection of catecholic butanes, including NDGA compounds, into animals
US7670817B2 (en) 2005-11-08 2010-03-02 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US20090324624A1 (en) * 2006-06-16 2009-12-31 Florida Atlantic University Chitin micro-particles as an adjuvant
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
AU2007325576B2 (en) * 2006-10-20 2013-01-10 Icos Corporation Compositions of Chk1 inhibitors
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2010042202A1 (en) 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
US20100189653A1 (en) * 2008-10-10 2010-07-29 Wendye Robbins Pyrone analogs for therapeutic treatment
US8202702B2 (en) 2008-10-14 2012-06-19 Seahorse Bioscience Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision
US8263413B1 (en) 2008-10-17 2012-09-11 Andrew S Hansen Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry
WO2010054167A2 (en) 2008-11-06 2010-05-14 University Of Miami Limited proteolysis of cd2ap and progression of renal disease
US20110314423A1 (en) 2009-03-12 2011-12-22 Panasonic Corporation Image display device and image display method
US8975241B2 (en) * 2009-10-08 2015-03-10 Song Ho Biomed Co., Ltd. Composition for treating and preventing obesity including high water-soluble 2-hydroxypropyl-betacyclodextrin as effective component
US20120251527A1 (en) 2009-11-06 2012-10-04 University Of Miami Podocyte specific assays and uses thereof
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2595623B1 (en) * 2010-07-19 2018-02-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
CA2930119C (en) 2010-10-19 2019-10-29 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
MX392972B (es) * 2012-04-13 2025-03-21 L&F Res Llc Metodo para utilizar ciclodextrina.

Also Published As

Publication number Publication date
US20210228616A1 (en) 2021-07-29
ES2959119T3 (es) 2024-02-20
MX2020000205A (es) 2022-06-06
EP4299121A3 (en) 2024-07-24
JP2018203747A (ja) 2018-12-27
CA2870316A1 (en) 2013-10-17
CA2870316C (en) 2022-04-19
EP2836221A4 (en) 2016-07-27
CN111419870A (zh) 2020-07-17
EP2836221B1 (en) 2023-07-05
JP2023178518A (ja) 2023-12-15
JP6491089B2 (ja) 2019-03-27
US20150065457A1 (en) 2015-03-05
EP4299121A2 (en) 2024-01-03
EP2836221A2 (en) 2015-02-18
US10195227B2 (en) 2019-02-05
US10980828B2 (en) 2021-04-20
MX2014012200A (es) 2015-06-17
US20230338412A1 (en) 2023-10-26
CN104244956B (zh) 2020-04-17
MX371073B (es) 2020-01-15
WO2013155485A2 (en) 2013-10-17
WO2013155485A3 (en) 2013-12-19
US20190262385A1 (en) 2019-08-29
JP2015512949A (ja) 2015-04-30
CN104244956A (zh) 2014-12-24
JP2021155436A (ja) 2021-10-07

Similar Documents

Publication Publication Date Title
MX392972B (es) Metodo para utilizar ciclodextrina.
MX2014010481A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
MX346428B (es) Metodo para tratar eccema.
DK2916860T3 (da) En sammensætning til behandling af diabetes, som omfatter oxyntomodulinanalog
BR112015003004A2 (pt) análogos de piridazina , 1-4 dissubstituída e métodos para tratar condições relacionadas com deficiência de smn
WO2012093809A3 (en) New bicyclic compound for modulating g protein-coupled receptors
BR112013019320A2 (pt) veículo para todos os terrenos.
EP2672967A4 (en) COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATING THEREFOR
PH12014502704B1 (en) Compounds and compositions for modulating egfr activity
DK3287142T3 (da) Fremgangsmåder til behandling af tilstande, som er forbundet med masp-2-afhængig komplementaktivering
WO2013003601A9 (en) Method for treating phytophotodermatitis
BR112013013576A2 (pt) método para tratar um hidrocarboneto contendo mercaptanos, composição de solução aquosa para tratar óleo bruto contendo mercaptanos, e, método de dois estágios para tratar um hidrocarboneto contendo mercaptanos
UY4153Q (es) Batería
BR112015002725A2 (pt) grampo bariátrico , e, método para instalar um grampo bariátrico.
UY34097A (es) Alineación de anticoagulante de cebado para extracción de sangre.
BR112013016241A2 (pt) composto, e, método para fabricar um composto
BR112013018945A2 (pt) processo para a preparação de 4-amino-5-fluoro-3-halo-6-(substituído)picolinatos.
BR112015013152A2 (pt) composição para tratamento de uma formação subterrânea , método para tratar uma formação subterrânea , e método para reduzir a viscosidade de óleo cru.
EA201390616A1 (ru) ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2
BR112015002493A2 (pt) composto , composição farmacêutica , método para o tratamento do câncer , processo para a preparação de uma composição farmacêutica , conjunto , utilização de um composto e invenção.
MX2014006157A (es) Moduladores mejoradores de la actividad de hec1 y metodos para los mismos.
EP2862936A4 (en) Oxidoreductase reaction control and use thereof
BR112013019798A2 (pt) composições bakuchiol para tratamento de hiperpigmentação pós-inflamatória.
MX2015007778A (es) Prediccion de bioactivacion molecular.
UY4152Q (es) Batería